Metabolic Indices and Cardiometabolic Risk Assessment

Cardiometabolic risk encompasses the likelihood of developing cardiovascular disease and metabolic disorders such as type 2 diabetes. Traditional metrics, including body mass index and waist circumference, offer limited insight into lipid distribution and metabolic dysfunction. In recent years, composite indices that combine anthropometric and biochemical parameters have emerged to refine risk stratification. Among these, the lipid accumulation product (LAP), visceral adiposity index (VAI) and the product of triglycerides and glucose (TyG) integrate measures of central adiposity and circulating lipid or glycaemic markers to approximate visceral fat burden and insulin resistance. Such indices correlate strongly with systemic inflammation, dyslipidaemia and endothelial dysfunction, and offer improved predictive accuracy for metabolic syndrome, new-onset diabetes and cardiovascular events. Globally, they have been applied in diverse populations from older adults to middle-aged cohorts, informing public health screening and guiding early intervention. By capturing underlying pathophysiological processes, metabolic indices facilitate personalised risk assessment, support lifestyle and pharmacological decision making and hold promise for reducing the burden of cardiometabolic disease.

Research from Nature Portfolio

Recent studies have evaluated the integration of inflammatory biomarkers with established metabolic indices. In a cohort of older adults, low-grade inflammation markers such as tumour necrosis factor-α and high-mobility group box-1 protein were elevated in individuals with metabolic syndrome and added discriminative power beyond traditional anthropometry. Analysis of receiver operating characteristic curves confirmed that LAP remained the most robust single anthropometric index, while novel immunological thresholds demonstrated potential as complementary predictors. Earlier work assessed the comparative accuracy of VAI, LAP and TyG in identifying prediabetes and diabetes in a general adult population. Both TyG and LAP showed superior discrimination (area under the curve values above 0.74) and demonstrated sex-specific optimal cut-off values, highlighting their utility in early detection of glucose dysregulation and targeting preventive measures.

Metabolic Indices and Cardiometabolic Risk Assessment publication trend

The graph below shows the total number of articles in metabolic indices and cardiometabolic risk assessment across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolic syndrome: A cluster of interrelated conditions—central obesity, dyslipidaemia, hypertension and hyperglycaemia—predisposing to cardiovascular disease and diabetes.

Lipid accumulation product (LAP): An index combining waist circumference and fasting triglyceride concentration to estimate visceral lipid deposition.

Visceral adiposity index (VAI): A sex-specific formula incorporating waist circumference, body mass index, triglycerides and HDL cholesterol to infer visceral fat function.

Product of triglycerides and glucose (TyG): A surrogate marker of insulin resistance calculated as the logarithmic product of fasting triglyceride and glucose levels.

Area under the curve (AUC): A measure of diagnostic accuracy derived from receiver operating characteristic analysis, reflecting the trade-off between sensitivity and specificity.

Insulin resistance: A physiological state in which target tissues exhibit diminished response to insulin, often preceding type 2 diabetes.

References

1. Enhanced Predictive Value of Lipid Accumulation Product for Identifying Metabolic Syndrome in the General Population of China. Nutrients (2023).
2. Assessment of metabolic syndrome predictors in relation to inflammation and visceral fat tissue in older adults. Scientific Reports (2023).
3. Visceral adiposity index (VAI), lipid accumulation product (LAP), and product of triglycerides and glucose (TyG) to discriminate prediabetes and diabetes. Scientific Reports (2019).
4. A prospective cohort study on the effect of lipid accumulation product index on the incidence of cardiovascular diseases. Nutrition & Metabolism (2024).
5. Gender-specific accuracy of lipid accumulation product index for the screening of metabolic syndrome in general adults: a meta-analysis and comparative analysis with other adiposity indicators. Lipids in Health and Disease (2024).